Search research articles
Contact Us
Filters
Showing results (91-100 of 153) with videos related to
Page
of 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
Antonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 10, 2019
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, et al.
Cancers
|
February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)
Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.
International Journal of Cancer
|
March 9, 2022
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial
Elodie Maille, Jérôme Levallet, Fatéméh Dubois, et al.
Translational Oncology
|
September 6, 2025
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial
Julien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 2, 2023
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
Guénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, et al.
Chest
|
March 11, 2026
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group
Grégoire Justeau, Laurent Greillier, Florent Vinas, et al.
Cancer Immunology, Immunotherapy : CII
|
June 21, 2022
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Renaud Descourt, Laurent Greillier, Maurice Perol, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 153) with videos related to
Sort By:
Page
of 16
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
Antonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 10, 2019
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, et al.
Cancers
|
February 15, 2022
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)
Laurent Greillier, Manon Gauvrit, Elena Paillaud, et al.
International Journal of Cancer
|
March 9, 2022
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial
Elodie Maille, Jérôme Levallet, Fatéméh Dubois, et al.
Translational Oncology
|
September 6, 2025
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial
Julien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 2, 2023
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
Guénaëlle Levallet, Fatéméh Dubois, Nicolas Elie, et al.
Chest
|
March 11, 2026
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group
Grégoire Justeau, Laurent Greillier, Florent Vinas, et al.
Cancer Immunology, Immunotherapy : CII
|
June 21, 2022
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Renaud Descourt, Laurent Greillier, Maurice Perol, et al.
Page
of 16